107 related articles for article (PubMed ID: 14597321)
1. Therapeutic gene transfer with herpes-based vectors: studies in Parkinson's disease and motor nerve regeneration.
Fink DJ; Glorioso J; Mata M
Exp Neurol; 2003 Nov; 184 Suppl 1():S19-24. PubMed ID: 14597321
[TBL] [Abstract][Full Text] [Related]
2. Enhanced functional recovery after proximal nerve root injury by vector-mediated gene transfer.
Natsume A; Wolfe D; Hu J; Huang S; Puskovic V; Glorioso JC; Fink DJ; Mata M
Exp Neurol; 2003 Dec; 184(2):878-86. PubMed ID: 14769380
[TBL] [Abstract][Full Text] [Related]
3. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 and GDNF delivered by HSV-mediated gene transfer after spinal root avulsion provide a synergistic effect.
Natsume A; Mata M; Wolfe D; Oligino T; Goss J; Huang S; Glorioso J; Fink DJ
J Neurotrauma; 2002 Jan; 19(1):61-8. PubMed ID: 11852979
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI
Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration.
Natsume A; Mata M; Goss J; Huang S; Wolfe D; Oligino T; Glorioso J; Fink DJ
Exp Neurol; 2001 Jun; 169(2):231-8. PubMed ID: 11358438
[TBL] [Abstract][Full Text] [Related]
7. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
8. Viral vectors in the treatment of Parkinson's disease.
Latchman DS; Coffin RS
Mov Disord; 2000 Jan; 15(1):9-17. PubMed ID: 10634236
[TBL] [Abstract][Full Text] [Related]
9. Experiments in a Parkinson's rat model.
Pallini R; Consales A; Lauretti L; Fernandez E
Science; 1997 Jul; 277(5324):389-90. PubMed ID: 9518368
[No Abstract] [Full Text] [Related]
10. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
Lapchak PA; Araujo DM; Hilt DC; Sheng J; Jiao S
Brain Res; 1997 Nov; 777(1-2):153-60. PubMed ID: 9449424
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal gene delivery of glial cell line-derived neurotrophic factor ameliorated paraplegia in rats after spinal ischemia.
Chou AK; Yang LC; Wu PC; Wong WT; Liu GS; Chen JT; Howng SL; Tai MH
Brain Res Mol Brain Res; 2005 Feb; 133(2):198-207. PubMed ID: 15710236
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.
Tereshchenko J; Maddalena A; Bähr M; Kügler S
Neurobiol Dis; 2014 May; 65():35-42. PubMed ID: 24440408
[TBL] [Abstract][Full Text] [Related]
13. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P
Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911
[TBL] [Abstract][Full Text] [Related]
14. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion.
McGrath J; Lintz E; Hoffer BJ; Gerhardt GA; Quintero EM; Granholm AC
Cell Transplant; 2002; 11(3):215-27. PubMed ID: 12075987
[TBL] [Abstract][Full Text] [Related]
15. Rescue and sprouting of motoneurons following ventral root avulsion and reimplantation combined with intraspinal adeno-associated viral vector-mediated expression of glial cell line-derived neurotrophic factor or brain-derived neurotrophic factor.
Blits B; Carlstedt TP; Ruitenberg MJ; de Winter F; Hermens WT; Dijkhuizen PA; Claasens JW; Eggers R; van der Sluis R; Tenenbaum L; Boer GJ; Verhaagen J
Exp Neurol; 2004 Oct; 189(2):303-16. PubMed ID: 15380481
[TBL] [Abstract][Full Text] [Related]
16. Glial cell line-derived neurotrophic factor enhances axonal regeneration following sciatic nerve transection in adult rats.
Chen ZY; Chai YF; Cao L; Lu CL; He C
Brain Res; 2001 Jun; 902(2):272-6. PubMed ID: 11384621
[TBL] [Abstract][Full Text] [Related]
17. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
[TBL] [Abstract][Full Text] [Related]
18. Gene transfer of glial cell line-derived neurotrophic factor promotes functional recovery following spinal cord contusion.
Tai MH; Cheng H; Wu JP; Liu YL; Lin PR; Kuo JS; Tseng CJ; Tzeng SF
Exp Neurol; 2003 Oct; 183(2):508-15. PubMed ID: 14552891
[TBL] [Abstract][Full Text] [Related]
19. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
[TBL] [Abstract][Full Text] [Related]
20. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
